Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70354 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Garyn Metoyer and 10 co-authors. Institution: NYU Langone Department of Surgery, New York, New York, USA. Major MEDLINE topics: Kidney Transplantation, Glucagon-Like Peptide-1 Receptor Agonists, Postoperative Complications, Hypoglycemic Agents. Cited 6 times so far (Crossref); 30 references. Funded by: NIDDK NIH HHS, National Institute of Allergy and Infectious Diseases, Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation.
Topics: Diabetes mellitus
Abstract (original language)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP1RA) provide survival benefits in people with diabetes, including kidney transplant (KT) recipients with pre‐existing diabetes. Post‐transplant diabetes mellitus (PTDM) is common, but the benefits of GLP1RAs remain undefined in this population. We aim to describe current usage practices and outcomes in PTDM.
Methods
We used USRDS and Medicare claims data (2013–2022) to conduct a drug utilization profile of GLP1RA among 7681 first‐time adult KT recipients with PTDM. We used survival analysis to estimate GLP1RA initiation incidence and associated patient, graft, and safety outcomes.
Results
A total of 430 adult KT recipients with PTDM were prescribed GLP1RA. Dulaglutide was the most commonly prescribed medication (46.1%). The 5‐year cumulative incidence of GLP‐1 receptor agonists prescription was 9.8%. Median (interquartile range) time from PTDM diagnosis to first prescription was 1.7 (0.6, 3.4) years. GLP1RA use was not associated with a difference in the risk of mortality or graft failure but was associated with a 1.80‐fold (95% confidence interval [CI]: 1.11–2.91) increased risk of diabetic retinopathy. No increased risk of pancreatitis, biliary complications, or medullary thyroid cancer were identified.
Conclusions
GLP1RA use in KT recipients with PTDM was not associated with graft or patient survival, though longer follow‐up is necessary. GLP1RA use was associated with an increased risk of diabetic retinopathy, and care should be taken when initiating these agents.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- NYU Langone Department of Surgery, New York, New York, USA.
- Saint Louis University Department of Medicine, St. Louis, Missouri, USA.
- NYU Langone Department of Population Health, New York, New York, USA.
- NYU Langone Department of Medicine, New York, New York, USA.
ORCID profiles: Garyn Metoyer, Harriz Z Whiteson, Yusi Chen, Yiting Li, Chenxi Gao, Gayathri Menon, Sunjae Bae, Krista L Lentine, Dorry L Segev, Mara A McAdams-DeMarco, Babak J Orandi
Funding
- NIDDK NIH HHS
- National Institute of Allergy and Infectious Diseases
- Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation
- National Institute of Diabetes and Digestive and Kidney Diseases
Cite
APA
Metoyer, G., Whiteson, H. Z., Chen, Y., Li, Y., Gao, C., Menon, G., Bae, S., Lentine, K. L., Segev, D. L., McAdams-DeMarco, M. A., & Orandi, B. J. (2025). Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70354
Vancouver
Metoyer G, Whiteson HZ, Chen Y, Li Y, Gao C, Menon G, et al. Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70354
BibTeX
@article{Metoyer2025,
author = {Metoyer, Garyn and Whiteson, Harriz Z and Chen, Yusi and Li, Yiting and Gao, Chenxi and Menon, Gayathri and Bae, Sunjae and Lentine, Krista L and Segev, Dorry L and McAdams-DeMarco, Mara A and Orandi, Babak J},
title = {Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70354}
}
EUVIMED